Chronic pain

Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.

Retrieved on: 
Wednesday, February 28, 2024
Physician, FDA, Gout, Cardinal Health, Chronic pain, United, Negotiation, Nursing

GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Key Points: 
  • GLOPERBA® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
  • Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States¹.
  • The increase of GLOPERBA® manufacturing is to meet its potential demand and increased stocking needs in its distribution center.
  • For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .

Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

Retrieved on: 
Tuesday, February 27, 2024
PALO, AAPM, Neuropathic pain, First, MST, Chronic pain, Pain management, Patient, Poster, Lidocaine, American Academy, Birth control

Titled: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (First author: Srinivas Nalamachu, M.D.).

Key Points: 
  • Titled: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis (First author: Srinivas Nalamachu, M.D.).
  • In addition, patients treated with ZTlido® had a more significant reduction in opioid dose relative to a generic lidocaine 5% patch.
  • Regardless of the type of neuropathic pain, ZTlido® was associated with a greater opioid-sparing effect than a generic lidocaine 5% patch.
  • As a result, improved adhesion for ZTlido® is likely contributing to more optimal pain management and enable reduction/discontinuation of opioid dose.

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement

Retrieved on: 
Monday, February 26, 2024
PALO, Plaintiff, Sale, Chronic pain, Nursing

Each of the Plaintiffs and Virpax provides mutual releases of all claims that exist as of the date of the execution of the Settlement Term Sheet, whether known or unknown, arising from any allegations set forth in the Action.

Key Points: 
  • Each of the Plaintiffs and Virpax provides mutual releases of all claims that exist as of the date of the execution of the Settlement Term Sheet, whether known or unknown, arising from any allegations set forth in the Action.
  • The Plaintiffs’ release relates to claims against Virpax only, which does not affect their claims against Mr. Mack.
  • Plaintiffs’ release as to Virpax is conditioned upon Virpax’s Initial Payment.
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met

Retrieved on: 
Monday, February 26, 2024
Therapy, PALO, Patient, Chronic pain, Health, Lidocaine, Nursing

PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced ZTlido® has reached three major milestones since it launched in October 2018.

Key Points: 
  • Over one million patients are estimated to have been treated with ZTlido® since its launch according to Symphony Health prescription data.
  • Patients report 89% satisfaction with ZTlido®, in a 2023 patient survey conducted by Scilex (n=100, rating as “completely” or “mostly” satisfied with ZTlido® treatment).
  • ZTlido has been strategically designed to address poor adhesion, a leading complaint associated with other currently marketed topical lidocaine products.
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

Joni and Friends celebrates 45 years of disability ministry

Retrieved on: 
Monday, February 26, 2024
Neck, Diving, Tetraplegia, Hope, Hardship, Disability, Chronic pain, House, Practice, Joni

This year marks the 45th anniversary since the founding of the international disability ministry Joni and Friends.

Key Points: 
  • This year marks the 45th anniversary since the founding of the international disability ministry Joni and Friends.
  • For the past four-and-a-half decades, Joni and Friends has provided practical help and Gospel hope to individuals living with disability around the world.
  • Joni said she is astonished at what God has done through 45 years of ministry at Joni and Friends.
  • “God has done—and continues to do—astonishing things through Joni and Friends and 45 years of ministry is an astounding milestone!

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Retrieved on: 
Friday, February 23, 2024
Fever, European Commission, EMA, ALS, Committee, MND, Myalgia, Intracranial pressure, BIIB, Cerebrospinal fluid, Pain, Hope, Biogen, European, SOD1, Arthralgia, Civil service commission, Biomarker, Fatigue, CHMP, AFL, European Medicines Agency, Protein, Disease, UZ Leuven, Mutation, Myelitis, Neurology, Aseptic meningitis, Research, Chronic pain, Vaccine

If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Key Points: 
  • If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
  • “The CHMP’s positive opinion reinforces the impact QALSODY can have in SOD1-ALS and further demonstrates Biogen’s commitment to address the unmet needs of people living with ALS and neuromuscular diseases,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.
  • Trends towards improvement in the physical abilities of participants who received QALSODY were seen compared to those who received placebo, as measured by the ALS Functional Ratings Scale-Revised (ALSFRS-R).
  • Serious neurologic events, including myelitis and/or radiculitis; papilledema and elevated intracranial pressure; and aseptic meningitis have also been reported.

Calian Wins Contract to Support Clinical Trial for ZYUS Life Sciences’ Lead Drug Product Candidate

Retrieved on: 
Tuesday, February 20, 2024
CGY, Clinical trial, TSX, Pain, Data management, Learning, Safety, Contract research organization, Chronic pain, Patient, Knowledge, Medical writing, Partnership, Pharmaceutical industry

Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules.

Key Points: 
  • Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules.
  • “Calian will apply our industry-leading expertise to support this Phase 2 Clinical Trial and further ZYUS’ pursuit of transformational impact on patients’ lives,” says Derek Clark, President, Calian Health.
  • Calian will provide full-service, end-to-end expertise to support this trial, including medical writing, regulatory affairs, clinical operations, site monitoring, data management, medical monitoring and quality assurance.
  • By collaborating with an industry leading contract research organization with extensive experience in clinical trial management, we can leverage invaluable knowledge and expertise."

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

Retrieved on: 
Tuesday, February 20, 2024
PALO, Prevalence, Neck pain, Lidocaine, Physical medicine and rehabilitation, Neurology, Anesthesiology, American Medical Association, JAMA, Outline of health sciences, Disability, Chronic pain, Behavioural sciences, COVID, Patient, Journal, Neck, Psychiatry, Clutch (eggs), Rehabilitation, Pharmaceutical industry

PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Key Points: 
  • PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.
  • The primary outcome measure was mean reduction in average neck pain coupled with the Patient Global Impression of Change.
  • Neck pain, or cervicalgia, is one of the most common pain presentations in U.S. and the 4th leading cause of disability.
  • According to a 2020 JAMA publication (Journal of the American Medical Association), the U.S. low back and neck pain market is estimated at $134.5B.4

AIS Healthcare Recognizes Brain Injury Awareness Month

Retrieved on: 
Thursday, March 7, 2024
Health, Consumer, Other Health, General Health, Pharmaceutical, People with Disabilities, Brain damage, Quality of life, TBI, Chronic pain, Pain management, Patient, Family, Brain, CDC, TDD, Research, Medical device

AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March as Brain Injury Awareness Month.

Key Points: 
  • AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March as Brain Injury Awareness Month.
  • This month reminds us of the importance of improving the quality of life for people impacted by brain injury through elevating awareness and advocacy and delivering the highest-quality healthcare.
  • “This month and every month, we seek to empower individuals living with a brain injury by delivering the best possible in-home healthcare services and pain management solutions.
  • To find more ways to support the brain injury community, contact your local brain injury association by visiting here .

Nalu Medical, Inc. Closes $85 Million Series E Round

Retrieved on: 
Tuesday, March 5, 2024
Neurology, Biotechnology, Nanotechnology, Surgery, Health, Medical Devices, Health Technology, Technology, Pura, Medicine, Neuropathic pain, PNS, General partnership, Physician, Novo, Spinal cord stimulator, Standard of care, Health care, Chronic pain, Patient, SCS

Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.

Key Points: 
  • Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.
  • Series E was led by Novo Holdings (Novo) with $65M of the total closing in late-December 2023.
  • Also participating in the round were all existing significant investors: Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.
  • “The Nalu Team is committed to addressing the unmet needs of patients suffering from chronic intractable neuropathic pain.